Lomustine and Bevacizumab in Progressive Glioblastoma
German Cancer Research Center · Heidelberg University · +20 more institutions
Abstract
Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma.
-methylguanine-DNA methyltransferase (MGMT) was assessed. Health-related quality of life and neurocognitive function were evaluated at baseline and every 12 weeks. The primary end point of the trial was overall survival.
Citation impact
- FWCI
- 44.43
- Percentile
- 100%
- References
- 27
Authors
23- WWWolfgang WickCorresponding
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, VIB-KU Leuven Center for Cancer Biology
- TGThierry Gorlia
Heidelberg University, University Hospital Heidelberg, VIB-KU Leuven Center for Cancer Biology, European Organisation for Research and Treatment of Cancer
- MBMartin Bendszus
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, VIB-KU Leuven Center for Cancer Biology
- MTMartin Taphoorn
Heidelberg University, University Hospital Heidelberg, VIB-KU Leuven Center for Cancer Biology, Medisch Centrum Haaglanden
- FSFelix Sahm
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, VIB-KU Leuven Center for Cancer Biology
Topics & keywords
- Lomustine
- Medicine
- Bevacizumab
- Hazard ratio
- Internal medicine
- Clinical endpoint
- Progression-free survival
- Confidence interval
- Good health and well-being